Jamjoom Pharmaceuticals Factory Valuation
Is 4015 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 4015 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 4015 (SAR157.4) is trading above our estimate of fair value (SAR106.08)
Significantly Below Fair Value: 4015 is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 4015?
Key metric: As 4015 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is 4015's PE Ratio? | |
|---|---|
| PE Ratio | 31.5x |
| Earnings | ر.س349.40m |
| Market Cap | ر.س11.02b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 8.6x |
| Enterprise Value/EBITDA | 26.9x |
| PEG Ratio | 2.8x |
Price to Earnings Ratio vs Peers
How does 4015's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 53.5x | ||
2070 Saudi Pharmaceutical Industries and Medical Appliances | 162.3x | 33.5% | ر.س3.8b |
4016 Middle East Pharmaceutical Industries | 29.5x | n/a | ر.س2.4b |
000623 Jilin Aodong Pharmaceutical Group | 14.8x | 38.1% | CN¥21.4b |
3933 United Laboratories International Holdings | 7.2x | 5.0% | HK$22.3b |
4015 Jamjoom Pharmaceuticals Factory | 31.5x | 11.1% | ر.س11.0b |
Price-To-Earnings vs Peers: 4015 is good value based on its Price-To-Earnings Ratio (31.5x) compared to the peer average (53.5x).
Price to Earnings Ratio vs Industry
How does 4015's PE Ratio compare vs other companies in the Asian Pharmaceuticals Industry?
| 13 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 13 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: 4015 is expensive based on its Price-To-Earnings Ratio (31.5x) compared to the Asian Pharmaceuticals industry average (24.1x).
Price to Earnings Ratio vs Fair Ratio
What is 4015's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 31.5x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 4015's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | ر.س157.40 | ر.س174.38 +10.8% | 2.3% | ر.س180.00 | ر.س169.50 | n/a | 4 |
| Dec ’25 | ر.س156.40 | ر.س174.38 +11.5% | 2.3% | ر.س180.00 | ر.س169.50 | n/a | 4 |
| Nov ’25 | ر.س169.00 | ر.س172.94 +2.3% | 3.5% | ر.س180.00 | ر.س163.75 | n/a | 4 |
| Oct ’25 | ر.س185.80 | ر.س172.94 -6.9% | 3.5% | ر.س180.00 | ر.س163.75 | n/a | 4 |
| Sep ’25 | ر.س177.40 | ر.س162.25 -8.5% | 9.3% | ر.س180.00 | ر.س143.00 | n/a | 3 |
| Aug ’25 | ر.س155.20 | ر.س146.62 -5.5% | 5.0% | ر.س156.86 | ر.س140.00 | n/a | 3 |
| Jul ’25 | ر.س144.60 | ر.س146.62 +1.4% | 5.0% | ر.س156.86 | ر.س140.00 | n/a | 3 |
| Jun ’25 | ر.س132.60 | ر.س146.62 +10.6% | 5.0% | ر.س156.86 | ر.س140.00 | n/a | 3 |
| May ’25 | ر.س133.00 | ر.س142.10 +6.8% | 1.1% | ر.س143.31 | ر.س140.00 | n/a | 3 |
| Apr ’25 | ر.س128.80 | ر.س132.10 +2.6% | 7.2% | ر.س143.31 | ر.س120.00 | n/a | 3 |
| Mar ’25 | ر.س144.40 | ر.س118.28 -18.1% | 10.8% | ر.س133.00 | ر.س101.85 | n/a | 3 |
| Feb ’25 | ر.س138.60 | ر.س118.28 -14.7% | 10.8% | ر.س133.00 | ر.س101.85 | n/a | 3 |
| Jan ’25 | ر.س114.60 | ر.س118.28 +3.2% | 10.8% | ر.س133.00 | ر.س101.85 | n/a | 3 |
| Dec ’24 | ر.س114.00 | ر.س118.28 +3.8% | 10.8% | ر.س133.00 | ر.س101.85 | ر.س156.40 | 3 |
| Nov ’24 | ر.س108.40 | ر.س115.28 +6.3% | 11.8% | ر.س134.00 | ر.س101.85 | ر.س169.00 | 3 |
| Oct ’24 | ر.س118.40 | ر.س115.28 -2.6% | 11.8% | ر.س134.00 | ر.س101.85 | ر.س185.80 | 3 |
| Sep ’24 | ر.س116.20 | ر.س122.00 +5.0% | 9.8% | ر.س134.00 | ر.س110.00 | ر.س177.40 | 2 |
| Aug ’24 | ر.س120.80 | ر.س122.00 +1.0% | 9.8% | ر.س134.00 | ر.س110.00 | ر.س155.20 | 2 |
Analyst Forecast: Target price is less than 20% higher than the current share price.
Discover undervalued companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/25 09:35 |
| End of Day Share Price | 2024/12/25 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Jamjoom Pharmaceuticals Factory Company is covered by 4 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Madhu Appissa | Al Rajhi Capital |
| null null | J.P. Morgan |
| Tarek Sleiman | J.P. Morgan |